ARCHIVES

FDA Designates Zometa For Priority Review.

This article is from The Cancer Letter archive.

Vol. 27 No. 44 | November 30, 2001

Download PDF Visit The Full Archive

Related Articles

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

April 25, 2014

PDX Shows 27% Response In T-Cell Lymphoma In Study

December 26, 2008

CCOP Review Completed; 72 Applications Submitted, 23 More For Minority CCOP

December 1, 1989

What? Only a “B”? NLST Co-Principal Investigator Begs to Differ with USPSTF Lung Cancer Screening Grade

August 9, 2013

Monoclonal Antibody Improves AML Response To Therapy

July 26, 2002

Henschke: I-ELCAP Plans to Enroll 100,000 Patients In Controversial Screening Trial

June 24, 2011